Axsome Q3 Revenue Jumps 52% to $259.7M, Tops $1B Annualized Run Rate
AXSM sits 17% above its 52-week low of $123.5 on elevated volume (2.8× avg).
Summary
Axsome reported third-quarter net product revenue of $259.7 million, up 52% year over year, and narrowed its net loss to $12.9 million while guiding that current cash funds operations into cash flow positivity.
Key Events · Earnings and Guidance · AXSM
-
Q3 Revenue Up 52% to $259.7M
Total net product revenue reached $259.7 million, up from $171.0 million a year earlier, crossing a >$1 billion annualized run rate.
-
Net Loss Narrows to $12.9M
The net loss was $12.9 million, or $(0.25) per share, versus $47.2 million, or $(0.94) per share, a year ago; the quarter included $26.4 million of stock-based compensation.
-
Cash Funds Runway to Cash Flow Positivity
Cash and equivalents stood at $313.9 million at September 30, 2026, and management believes current cash is sufficient to fund operations into cash flow positivity.
-
AUVELITY Leads at $207.6M
AUVELITY net product sales rose 53% year over year to $207.6 million, with new-to-brand prescriptions in patients 65 and older up 211% versus the prior-year quarter.
Analysis · AXSM · Life Sciences
The commercial engine is now clearly profitable at the operating line: revenue of $259.7 million grew 52% year over year, and the quarterly net loss narrowed to $12.9 million from $47.2 million. Management states that current cash of $313.9 million funds operations into cash flow positivity. AUVELITY did the heavy lifting at $207.6 million (+53%), and the Alzheimer's disease agitation label added April 30, 2026 is showing up in the 65-and-over prescription data (new-to-brand scripts up 211% year over year in that cohort). The offset is spending: SG&A rose 35% to $203.1 million and R&D 26% to $50.6 million, so the path to sustained profitability depends on holding that revenue growth rate. The pipeline calendar is dense — ENGAGE topline in 1Q 2027 and the AXS-12 PDUFA date of May 1, 2027 are the nearest binary events.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AXSM was trading at $144.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $123.50 to $260.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.